Our agency in brief

ANRS MIE (Emerging Infectious Diseases), an autonomous agency of Inserm, supports research to provide scientific responses to infectious diseases in times of crisis and over the long term.

Last updated on 14 February 2024

An extensive research field

Successor to the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) – founded to respond to the urgency and extent of the HIV/AIDS epidemic – and to the Inserm REACTing consortium, ANRS MIE was created on 1 January 2021.

We facilitate, coordinate, evaluate and fund research into HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis, and emerging and re-emerging infectious diseases, such as COVID-19, viral haemorrhagic fevers and arboviruses.

We cover all areas of research: basic, translational, clinical, public health, and human and social sciences.


A unique governance model

Under the authority of the France’s Ministry of Higher Education and Research and Ministry of Health and Prevention, our agency federates an interinstitutional network of national and international physicians and researchers, patient organisations and civil society representatives, all fully involved in the agency’s governance and operation. This dynamic of co-construction guarantees project implementation in line with the expectations of the affected communities, and aims to limit the health, economic and social impacts of epidemics.

An international approach

We are developing a global health approach based on the One Health principles, which recognise the interdependence of animal, human and environmental health.  This helps to reinforce France’s response in the event of a crisis. Our agency is part of an international effort to fight epidemics, particularly in close cooperation with Europe and a network of partners in low- and middle-income countries.

Our desire is to make ANRS MIE an agency of researchers, for researchers, which breaks down barriers to research into infectious pathogens, and facilitates, supports and assists it.

Key figures (end 2022)

million euros total budget, 87% of which dedicated to funding research
new research projects funded and/or sponsored
40 000+
patients participating in clinical research

* Mandatory fields

Your details

Your request